Project Grant R01HL187848
Award Date 8/17/26
Completion Date 4/30/30
Dollars Obligated $774K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Michigan State University (doing business as Henry Ford Health+Michigan State University Health Sciences) $1,099,000 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop precision circadian medicine solutions for shift workers managing shift work disorder. The award funds research scaling digital health technologies, including consumer-based wearables, to track and manage circadian rhythms in nightshift...
- The National Heart, Lung, and Blood Institute awarded Duke University $778,772 on August 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolic and contractile dysfunction in heart failure with preserved ejection fraction. The research focuses on understanding the mechanistic link between mitochondrial impairment and loss of muscle strength and power in HFPEF, a systemic disorder affecting 3–4 million U.S. patients predominantly older women. The...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $1,088,692 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on interorganellar calcium signaling in health and disease. The award funds basic research examining how calcium signaling across the plasma membrane, endoplasmic reticulum, mitochondria, and lysosomes generates localized calcium microdomains that regulate transcriptional and metabolic programs...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $713,515 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate the neural mechanisms linking meal timing, circadian rhythms, and blood pressure control in diet-induced obesity. The project, titled "Food Intake Timing on Circadian Control of Blood Pressure in Diet-Induced Obesity," seeks to elucidate how the suprachiasmatic nucleus and...
- The National Heart, Lung, and Blood Institute awarded Emory University $100,228 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct longitudinal research examining associations between sleep health, protective factors against psychosocial adversity, and stress-related biomarkers including allostatic load and epigenetic age acceleration. The project analyzes multidimensional sleep health—encompassing regularity, satisfaction, alertness, timing,...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $756,607 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research leveraging nutrient sensing and lysosomal degradative capacity in macrophages as a therapeutic approach to cardiovascular disease. The project addresses atherosclerosis, the underlying cause of myocardial infarction, strokes, and heart failure, by investigating dysfunction in the autophagy-lysosome system...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $1,384,453 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the non-canonical roles of NIPBL in cardiomyocytes. The research addresses a gap in understanding why heterozygous NIPBL mutations—which account for over 60 percent of Cornelia de Lange Syndrome (CDLS) cases—lead to congenital heart disease or decreased cardiac function in at least 30 percent of CDLS...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $760,218 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate molecular mechanisms of cardiomyocyte maturation via RBFOX1 activation. The research investigates how circadian clock development in neonatal mammals parallels cardiomyocyte maturation, focusing on a circadian clock checkpoint comprising activators (ATF3/MEF2S) and a suppressor (NFIL3) that...
- The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded The Johns Hopkins University $248,999 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate reduced hypusination of EIF5A as a mechanism of heart failure with preserved ejection fraction (HFPEF). The research addresses mechanisms underlying HFPEF, which affects over half of heart failure patients but...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...